Systemic lupus erythematosus (SLE) is a chronic autoimmune disease marked by immune dysregulation, inflammation, and the production of autoantibodies that attack healthy tissues. Both genetic and environmental factors, such as UV exposure, infections, and diet, contribute to disease onset. A key feature of SLE is an imbalance in T-cell subtypes, particularly reduced regulatory T cells (Tregs) and increased pro-inflammatory Th17 and Th1 cells. This imbalance is accompanied by elevated cytokines such as IL-6, IL-17, and IFN-γ. Emerging evidence highlights the role of gut microbiota in modulating immune responses, with dysbiosis implicated in disrupting tolerance and promoting inflammation in SLE. As a result, gut-targeted interventions, including probiotic therapy, are being explored as adjunctive treatments.
Research shows that specific probiotic strains, such as lactobacillus rhamnosus, l. reuteri, and Bifidobacterium bifidum, can promote immune regulation in SLE by increasing Treg cells, reducing inflammatory cytokines, and restoring gut barrier function. These effects are mediated through short-chain fatty acid production, TLR signaling modulation, and enhanced mucosal immunity. Diet also plays a significant role; high-fiber, plant-based diets support microbial diversity and anti-inflammatory pathways. While standard treatments remain essential, probiotics and dietary strategies may enhance disease control and patient well-being. More clinical trials are needed to confirm these benefits and inform personalized SLE management.
Reference: Mohamed AH, Shafie A, Al-Samawi RI, et al. The role of probiotics in promoting systemic immune tolerance in systemic lupus erythematosus. Gut Pathog. 2025 Jun 17;17(1):45. doi: 10.1186/s13099-025-00702-7. PMID: 40528248; PMCID: PMC12172233.
